KL-6 and SP-D, both markers of alveolar epithelial damage, have been considered in assessing patients at risk of developing post-COVID-19 pulmonary fibrosis, aiding in decisions regarding antifibrotic therapy and lung rehabilitation programs [43,44]. Here, SFTPD is linked to COVID-19.